01 8Trerief/Excegran
02 5Zonegran
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 44
2019 Revenue in Millions : 43
Growth (%) : 2
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 157
2019 Revenue in Millions : 155
Growth (%) : 1
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 138
2020 Revenue in Millions : 157
Growth (%) : 1
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 33
2020 Revenue in Millions : 42
Growth (%) : -15
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 128
2021 Revenue in Millions : 138
Growth (%) : -8
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 113
2022 Revenue in Millions : 128
Growth (%) : 1
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 132
2015 Revenue in Millions : 120
Growth (%) : 11
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 161
2016 Revenue in Millions : 150
Growth (%) : 8
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 140
2017 Revenue in Millions : 145
Growth (%) : -3%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 43
2016 Revenue in Millions : 53
Growth (%) : -18
LOOKING FOR A SUPPLIER?